Comparative Pharmacology
Head-to-head clinical analysis: CARBIDOPA LEVODOPA versus CARBIDOPA LEVODOPA AND ENTACAPONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBIDOPA LEVODOPA versus CARBIDOPA LEVODOPA AND ENTACAPONE.
CARBIDOPA; LEVODOPA vs CARBIDOPA, LEVODOPA AND ENTACAPONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability in the CNS and reducing peripheral side effects.
Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, replenishing depleted dopamine in the striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain and reducing peripheral side effects. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which prolongs the half-life and duration of action of levodopa by reducing its conversion to 3-O-methyldopa.
Initial: carbidopa 25 mg/levodopa 100 mg (1 tablet) orally three times daily; titrate based on response. Maintenance: usually 1 tablet (25/100) three to four times daily, up to 8 tablets/day. Immediate-release, extended-release, and oral disintegrating forms available.
One tablet (carbidopa 25 mg/levodopa 100 mg/entacapone 200 mg) orally up to a maximum of 8 tablets per day in divided doses. Optimal dose individualized based on response and tolerance.
None Documented
None Documented
Levodopa: 1-3 hours (short, requires frequent dosing); carbidopa: 1-2 hours. Clinically, the combination extends half-life but does not significantly alter terminal elimination.
Levodopa: 1-2 hours (short half-life necessitates frequent dosing with carbidopa to inhibit peripheral decarboxylation). Carbidopa: 2-3 hours. Entacapone: 1-2 hours (terminal half-life prolonged with levodopa). Clinical context: entacapone prolongs levodopa's half-life by inhibiting COMT.
Levodopa: primarily renal (70-80% as metabolites, including dopamine and homovanillic acid); carbidopa: renal (30% unchanged, remainder as metabolites). Fecal excretion is minimal (<5%).
Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) and unchanged drug (<1%); carbidopa: 70% renal as unchanged drug and metabolites; entacapone: 90% fecal (biliary), 10% renal.
Category A/B
Category A/B
Dopamine Precursor
Dopamine Precursor